Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6184)
All Articles published online
|
Publishing Process of This Article
|
Dec 27, 2014 (publication date) through May 6, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sun H, Zhu MS, Wu WR, Shi XD, Xu LB. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol 2014; 6(12): 830-835 [PMID: 25544869 DOI: 10.4254/wjh.v6.i12.830] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v6/i12/830.htm |
| Number | Citing Articles |
| 1 |
Yujie Zhao, Alex A. Adjei. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. The Oncologist 2015; 20(6): 660 doi: 10.1634/theoncologist.2014-0465
|
| 2 |
Lesley J. Scott. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers. Drugs 2018; 78(7): 747 doi: 10.1007/s40265-018-0903-9
|
| 3 |
Daniel da Motta Girardi, Tatiana Strava Correa, Marcela Crosara Teixeira, Gustavo Dos Santos Fernandes. Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. Journal of Gastrointestinal Cancer 2018; 49(3): 227 doi: 10.1007/s12029-018-0121-4
|
| 4 |
Zeynep Firtina Karagonlar, Dogukan Koc, Evin Iscan, Esra Erdal, Neşe Atabey. Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Science 2016; 107(4): 407 doi: 10.1111/cas.12891
|
| 5 |
Xiang-Jun Han, Hong-Ying Su, Hai-Bo Shao, Ke Xu. Prognostic factors of spontaneously ruptured hepatocellular carcinoma. World Journal of Gastroenterology 2015; 21(24): 7488-7494 doi: 10.3748/wjg.v21.i24.7488
|
| 6 |
Zibo Chen, Tao Yuan, Fangjie Yan, Song Ye, Qin Xie, Bo Zhang, Nengmin Lin, Qiaojun He, Bo Yang, Hong Zhu. CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling. BMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09520-5
|
| 7 |
Selvaraj Vimalraj. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. International Journal of Biological Macromolecules 2022; 221: 1428 doi: 10.1016/j.ijbiomac.2022.09.129
|
| 8 |
Ting Liu, Xin Liu, Wenhua Li. Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget 2016; 7(26): 40800 doi: 10.18632/oncotarget.8315
|
| 9 |
Wan-xin Peng, Er-meng Xiong, Lu Ge, Yan-ya Wan, Chun-li Zhang, Feng-yi Du, Min Xu, Reyaz Ahmed Bhat, Jie Jin, Ai-hua Gong. Egr-1 promotes hypoxia-induced autophagy to enhance chemo-resistance of hepatocellular carcinoma cells. Experimental Cell Research 2016; 340(1): 62 doi: 10.1016/j.yexcr.2015.12.006
|
| 10 |
Jian-Jun Gao, Zhen-Yan Shi, Ju-Feng Xia, Yoshinori Inagaki, Wei Tang. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World Journal of Gastroenterology 2015; 21(42): 12059-12070 doi: 10.3748/wjg.v21.i42.12059
|
| 11 |
Maple Ye Feng, Landon L. Chan, Stephen Lam Chan. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Current Oncology 2022; 29(8): 5489 doi: 10.3390/curroncol29080434
|
| 12 |
József Jászai, Mirko Schmidt. Trends and Challenges in Tumor Anti-Angiogenic Therapies. Cells 2019; 8(9): 1102 doi: 10.3390/cells8091102
|
| 13 |
Anti-Angiogenesis Strategies in Cancer Therapeutics. 2017; : xiii doi: 10.1016/B978-0-12-802576-5.00017-6
|
| 14 |
Wattana Leowattana, Tawithep Leowattana, PathompThep Leowattana. Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2023; 29(10): 1551-1568 doi: 10.3748/wjg.v29.i10.1551
|
| 15 |
Haijian Zhang, Min Yao, Wei Wu, Liwei Qiu, Wenli Sai, Junling Yang, Wenjie Zheng, Jianfei Huang, Dengfu Yao. Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma. Tumor Biology 2015; 36(12): 9373 doi: 10.1007/s13277-015-3678-6
|
| 16 |
Xiang-Yuan Luo, Kong-Ming Wu, Xing-Xing He. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. Journal of Experimental & Clinical Cancer Research 2021; 40(1) doi: 10.1186/s13046-021-01968-w
|
| 17 |
Huiying Huang, Hua Zhang, Baoshan Cao. A study protocol for an open‐label, single‐arm, single‐center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma. Thoracic Cancer 2024; 15(5): 427 doi: 10.1111/1759-7714.15208
|
| 18 |
André C. Teixeira, Ivelise R.C. Brasil, Alba F.C. Torres, Fabio Tavora. The Evaluation of Angiogenesis Markers in Hepatocellular Carcinoma and Precursor Lesions in Liver Explants From a Single Institution. Applied Immunohistochemistry & Molecular Morphology 2018; 26(5): 330 doi: 10.1097/PAI.0000000000000426
|
| 19 |
Wattana Leowattana, Tawithep Leowattana, PathompThep Leowattana. Systemic treatment for unresectable hepatocellular carcinoma. World Journal of Gastroenterology 2023; 29(10): 1407 doi: 10.3748/wjg.v29.i10.1407
|